[THP-adriamycin: status of the clinical development of a new anthracycline in France].
THP-adriamycin (pirarubicin) is a new anthracycline-analogue. In France, the drug is achieving the phase II studies and the step of phase III studies is going on. As this point of its development, it is already possible to conclude that the drug probably shares the same efficacy as adriamycine, especially in breast cancer, but exhibits a better tolerance in term of alopecia and cardiac toxicity, as predicted by preclinical studies. Its pharmacological properties make the drug an original compound, exciting for investigations in the field of loco-regional therapy.
Herait
P
P
Laboratoire Roger-Bellon, Neuilly-sur-Seine, France.
D000505:Alopecia / Q000139:chemically induced; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy; D004317:Doxorubicin / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000493:pharmacokinetics / Q000627:therapeutic use*; D004361:Drug Tolerance; D005602:France; D006333:Heart Failure / Q000139:chemically induced; D006801:Humans
D000970:Antineoplastic Agents; D004317:Doxorubicin; C027260:pirarubicin
THP-adriamycine: état du développement clinique d'une nouvelle anthracycline en France.